Compare Novo Nordisk A/S (NVO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs T Rowe Price Group Inc — how do they compare? Novo Nordisk A/S trades at $38.36 (market cap $165.31B), while T Rowe Price Group Inc trades at $105.28 (market cap $22.23B). The key difference: Novo Nordisk A/S is far larger — about 7.4× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and T Rowe Price Group Inc for 115 Days on average.
| NVO | TROW | |
|---|---|---|
Market Cap | $165.31B | $22.23B |
Volume | 11,432,838 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $63.98 | $121.68 |
52-Week Low | $35.29 | $86.19 |
Typical Hold Time | 116 Days | 115 Days |
Enterprise Value | $179.56B | $19.43B |
Dividend Yield | 4.71% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
T. Rowe Price Group (TROW) trades at $104.07, showing modest daily gains of 0.45%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a low P/E of 10.46 and robust profitability metrics. Recent earnings show two consecutive beats, with Q3 2026 results pending. The company maintains solid cash flow generation and recently announced a $1.30 dividend payment for September 2026, continuing its 40-year dividend growth streak.
TROW offers value characteristics with attractive valuation multiples and consistent dividend growth, though technical weakness and mixed analyst sentiment suggest near-term caution. Upside potential exists to the $112 consensus target, but investors face risks from market-sensitive revenue streams and ongoing net outflows despite AUM growth to $1.90 trillion as of August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
